Skip to Main Content

Paper Details

Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial.
J Immunother Cancer
54
2022
Author NameAffiliation
Anthony M JoshuaKinghorn Cancer Centre, St. Vincent's Hospital
  • 1 - 1

Datasets

Release 1.2